A practical reference on LC-MS/MS: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-07-05 and is reviewed periodically as new material appears.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
| Property | Value | Notes |
|---|---|---|
| Solubility | Soluble in dimethyl sulfoxide and some organic solvents; practically insoluble in water | Solvent choice affects laboratory handling |
| Typical storage | -20 °C, desiccated, protected from light | Common condition for research samples |
| Analytical method | Liquid chromatography–tandem mass spectrometry (LC-MS/MS) | Used for identification and quantification in biological or product samples |
| Common synonyms | GW501516, GW-501516, GSK-516, Endurobol | Names found in research and anti-doping literature |
| Regulatory status | Unapproved therapeutic; prohibited in competitive sport | Status can vary by country and context |
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
==== Natural "trans fats" in dairy products ==== Some trans fatty acids occur in natural fats and traditionally processed foods. Vaccenic acid occurs in breast milk, and some isomers of conjugated linoleic acid (CLA) are found in meat and dairy products from ruminants. Butter, for example, contains about 3% trans fat.
Biomolecular structure Mammalian Motif Finder MochiView Multiple EM for Motif Elicitation Nucleic acid sequence Protein primary structure Protein I-sites Sequence logo Sequence mining Structural motif Short linear motif Conserved sequence Protein domain
Psychedelic drug use can cause hallucinogen-induced psychotic disorder (HIPD). HIPD is a form of substance-induced psychosis. The symptoms of HIPD are psychosis with paranoia, delusions, hallucinations, disorganized thinking, disorganized behavior, or insomnia that continue after the effects of the drug. Individuals with a personal or family history of mental illness are at the highest risk for hallucinogen-induced psychotic disorder. HIPD due to psychedelics is most commonly associated with LSD, but can be caused by DMT, mescaline, and psilocybin as well. Hallucinogen-induced psychotic disorder is a medical emergency. Without treatment, the psychosis can persist for weeks or months. An atypical antipsychotic medication such as aripiprazole, quetiapine, olanzapine, or risperidone is used to treat HIPD. Psilocybin-induced states of mind share features with states experienced in psychosis and researchers have called for investigation of the relationship. Hallucinogen-induced psychotic disorder has been reported with psychedelics in small percentages of individuals, and the rates appear to be higher in people with schizophrenia. The rate of hallucinogen-induced psychotic disorder is 0.6% in randomized controlled trials that exclude individuals with bipolar disorder or schizophrenia. In studies that included individuals with schizophrenia, 3.8% developed hallucinogen-induced psychotic disorder.
== External links == World Anti-Doping Agency v. Thomas Bellchambers et al., Australian Football League, Australian Sports Anti-Doping Authority — Arbitral Award delivered by the Court of Arbitration for Sport Essendon Football Club v Chief Executive Officer of the Australian Sports Anti-Doping Authority (19 September 2014) [2014] FCA 1019 Hird v Chief Executive Officer of the Australian Sports Anti-Doping Authority (9 October 2014) [2014] FCA 1090 Hird v Chief Executive Officer of the Australian Sports Anti-Doping Authority (includes Summary) (30 January 2015) [2015] FCAFC 7 Hird v Chubb Insurance Company of Australia Ltd (3 May 2016) [2016] VSC 174 "Timeline: Essendon doping investigation: timeline". ABC News (Australian Broadcasting Corporation). 27 August 2013. Retrieved 21 August 2015. "Essendon Bombers out of 2013 AFL finals as James Hird accepts 12-month suspension". ABC Grandstand Sport (Australian Broadcasting Corporation. 27 August 2013. Retrieved 21 August 2015. "AFL announces Essendon out of this year's finals series, Hird banned and club fined $2 million". Herald Sun. Fox Sports Australia. 27 August 2013. Retrieved 21 August 2015. "The Essendon supplements saga – a full timeline of quotes". AFL.com.au website. 27 August 2013. Retrieved 21 August 2015.
Sources: en.wikipedia.org
Software models and simulations for SARS-CoV-2, including spread, functional mechanisms and properties, efficacy of potential treatments, transmission risks, vaccination modelling/monitoring, (computational fluid dynamics, computational epidemiology, computational biology/computational systems biology were developed by governments, universities, and companies. Modelling software and related software is also used to evaluate impacts on the environment and the economy.
The ribbons' conductance exceeds predictions by a factor of 10. The ribbons can function more like optical waveguides or quantum dots, allowing electrons to flow smoothly along the ribbon edges. In copper, resistance increases proportionally with length as electrons encounter impurities. Transport is dominated by two modes: one ballistic and temperature-independent, and the other thermally activated. Ballistic electrons resemble those in cylindrical carbon nanotubes. At room temperature, resistance increases abruptly at a specific length—the ballistic mode at 16 micrometers and the thermally activated mode at 160 nanometers (1% of the former length). Graphene electrons can traverse micrometer distances without scattering, even at room temperature.
== Personal life == He is the older of two children of Laura (née Sachtleben) Wittliff and William Albert Wittliff. Wittliff's brother William D. Wittliff was a noted American screenwriter and photographer. Various of Wittliff's and his brother's childhood experiences during World War II were depicted in the film Raggedy Man (1981). While in college, Wittliff was a member of the Kappa Sigma fraternity and a long-time supporter of his adopted UofL chapter, and later received the John G. Tower Distinguished Alumnus Award. He married Theresa H. "Mitzie" Wittliff (née Hano) and had two sons. Later she also became his collaborator as well as his data and business manager of the clinical and quality assurance laboratories. Wittliff is widely known as an Oenophile having served as President of the Kentucky Chapters of the American Wine Society and of the American Institute of Wine & Food. He was also a founding member of the Kentucky Chapter of Confrérie de la Chaîne des Rôtisseurs.
Sources: en.wikipedia.org
It binds and activates PPARδ, a nuclear receptor that influences gene expression related to fatty acid metabolism and energy balance. This mechanism has been studied mainly in animals and cell models, not established as a safe human therapy.
No. It is not an anabolic-androgenic steroid; it is a synthetic PPARδ agonist. Because it is banned in sport, it is sometimes grouped with doping agents even though its chemical class differs from steroids.
Human data are limited and development was discontinued, so major effects and long-term risks are not well characterized. Some early studies examined metabolic markers, but they do not provide a basis for unsupervised use.
No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.